Nitrofurantoin Syri (Nitrofurantoin Monohydrate)

Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that bind to bacterial ribosomal proteins and DNA, disrupting carbohydrate metabolism and cell‑wall synthesis. This interference impairs bacterial replication, producing a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations, especially within the urinary tract where the drug is concentrated.

The dosage of Nitrofurantoin Syri is determined by the prescribing clinician based on the patient’s renal function, infection severity, and local antimicrobial guidelines. The prescriber selects the appropriate strength, frequency, and duration, and the regimen should be followed exactly as written on the prescription label.

Safety data for nitrofurantoin during pregnancy are limited; it is generally avoided in the first trimester and near term because of potential fetal hemolysis. Use during lactation is considered compatible with breastfeeding, but the infant should be monitored for possible gastrointestinal upset. Decisions should be made by a healthcare professional weighing risks and benefits.

To place an order, submit an enquiry on the Nitrofurantoin Syri product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details, and assists with any required import documentation.

Nitrofurantoin differs from agents such as trimethoprim‑sulfamethoxazole or fluoroquinolones by achieving high concentrations in urine while maintaining low systemic exposure, which reduces the risk of certain systemic side effects. It is active against many common uropathogens, including some resistant strains, but is ineffective for infections caused by Pseudomonas or Proteus species. Choice of therapy depends on local resistance patterns and patient‑specific factors.

Nitrofurantoin Syri should be stored below 25 °C in a dry environment. Keep the tablets in the original packaging to protect them from moisture and light, and avoid storing them in areas with high humidity or temperature fluctuations. Do not refrigerate or freeze the product.

Nitrofurantoin Syri is taken orally, usually with a full glass of water. The tablets should be swallowed whole and can be taken with food to reduce gastrointestinal irritation, unless the prescribing information advises otherwise. The exact timing and frequency are specified by the prescriber and must be adhered to for optimal efficacy.

The most serious adverse reactions include pulmonary toxicity such as interstitial lung disease or acute pneumonitis, severe hepatic injury, and hypersensitivity reactions like Stevens‑Johnson syndrome or hemolytic anemia in patients with G6PD deficiency. Early recognition of respiratory symptoms, jaundice, or rash is essential, and the medication should be discontinued and medical attention sought immediately if these occur.

Nitrofurantoin Syri is contraindicated in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to nitrofurantoin or other nitrofurans, and individuals with glucose‑6‑phosphate dehydrogenase deficiency due to the risk of hemolysis. Caution is also advised for pregnant women in the first trimester and near term, and for patients with a history of pulmonary or hepatic disease.